Avanos Medical(US:AVNS)2026-02-24 21:28Financial Performance - In 2025, total net sales reached $701.2 million, a 1.9% increase from $687.8 million in 2024, and a 2.2% increase from $673.3 million in 2023[175]. - Specialty Nutrition Systems net sales were $432.9 million in 2025, up 9.2% from $396.4 million in 2024, driven by strong demand for enteral feeding and neonate solutions[175][178]. - Pain Management and Recovery segment net sales were $237.8 million in 2025, a 1.5% increase from $234.2 million in 2024, with radiofrequency ablation solutions growing by 10.1%[175][179]. - North America net sales were $543.9 million in 2025, a slight decrease of 0.2% from $545.0 million in 2024[182]. - Total Operating Income showed a loss of $61.6 million in 2025, an improvement from a loss of $396.2 million in 2024, primarily due to lower goodwill impairment[194]. - Adjusted Operating Profit increased to $67.1 million in 2025 from $87.3 million in 2024, reflecting higher sales volume despite the operating loss[195]. - The company reported $74.7 million of cash provided by operating activities for the year ended December 31, 2025[212]. Goodwill and Impairment - The company recorded a goodwill impairment of $77.0 million in Q2 2025 and $336.5 million in Q4 2024, reflecting a decline in market capitalization[157][159]. - Goodwill impairment of $77.0 million was recorded in 2025, significantly impacting the consolidated operating results[201]. - The company experienced a decrease in market capitalization, prompting an interim goodwill impairment test that resulted in a $336.5 million impairment recorded in the fourth quarter of 2024[228]. - The company recorded a goodwill impairment of $77.0 million in the second quarter of 2025 due to the fair value of the Pain Management and Recovery reporting unit being below its carrying value[226]. Transformation and Acquisitions - The Transformation Process initiated in January 2023 aims to restructure operations, with expected annualized savings between $15.0 million and $20.0 million from new initiatives[160][164]. - The Nexus Acquisition was completed on September 11, 2025, for a total purchase price of $27.0 million, with potential additional contingent cash consideration of up to $20.0 million[166]. - The Diros Acquisition was finalized on July 24, 2023, for approximately $53.0 million, funded by proceeds from the Revolving Credit Facility[167]. - The company incurred $1.5 million in acquisition and integration-related charges in 2025, primarily related to the acquisition of Nexus[196]. Costs and Expenses - Total Cost of Products Sold increased to $347.3 million in 2025 from $306.5 million in 2024, primarily due to increased tariffs and unfavorable pricing for certain product lines[185]. - Research and Development expenses decreased to $23.3 million in 2025 from $26.2 million in 2024, with Specialty Nutrition Systems accounting for $17.2 million and Pain Management and Recovery for $5.1 million[187]. - Selling and General Expenses decreased from $318.5 million in 2024 to $315.6 million in 2025, driven by savings from the Transformation Process and increased spending discipline[190]. - In 2025, the company incurred $32.4 million in costs related to the Transformation Process, compared to $8.9 million in 2024[165]. Debt and Cash Management - The company has a credit agreement with a total principal amount of $500.0 million, which includes a $125.0 million term loan and a $375.0 million revolving credit facility, maturing on June 24, 2027[214]. - As of December 31, 2025, the effective interest rate on the Term Loan Facility was 5.6%[215]. - Interest Expense decreased to $7.8 million in 2025 from $12.2 million in 2024, indicating improved debt management[206]. - As of December 31, 2025, cash and cash equivalents decreased by $17.9 million to $89.8 million, driven by $31.6 million in capital expenditures and $28.0 million used for the acquisition of Nexus[212]. - The company is in compliance with all debt covenants as of December 31, 2025[216]. Tax and Cash Flow - The overall effective tax rate was (10.1)% for 2025, compared to 4.2% in 2024, reflecting changes in profitability and tax strategies[208]. - The company expects operating cash flow to be sufficient to meet working capital requirements and fund capital expenditures in the next twelve months[209]. Market Risks - A 10% change in the exchange rate of the U.S. dollar against foreign currencies would have an effect of $0.9 million on the consolidated financial position, results of operations, and cash flows[242]. - A 10% change in the exchange rate of the U.S. dollar against foreign currency translation exposures would impact stockholders' equity by approximately $16.8 million[244]. - Increases in commodity prices could adversely affect earnings if selling prices are not adjusted accordingly[245]. - The company is subject to price risk for utilities and manufacturing inputs used in manufacturing operations[246].